New insights into the roles of ncRNA in the STAT3 pathway

Future Oncology

Volumn 8, Issue 6, 2012, Pages 723-730

  Zhang, Junxia ^a,b   Zhang, Anlin ^a,b   Wang, Yingyi ^c   Liu, Ning ^c   You, Yongping ^c   Kang, Chunsheng ^a,b   Pu, Peiyu ^a,b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b Variation and Regeneration   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

cancer; lncRNA; miRNA; STAT3

Indexed keywords

MICRORNA; MICRORNA 124; MICRORNA 125B; MICRORNA 155; MICRORNA 182; MICRORNA 21; MICRORNA 24; STAT3 PROTEIN; UNTRANSLATED RNA;

GENE LOCUS; GENETIC TRANSCRIPTION; HUMAN; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

HUMANS; MICRORNAS; RNA, UNTRANSLATED; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84863706288     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.52     Document Type: Review

References (63)

1. Germain D, Frank DA. Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin. Cancer Res. 13(19), 5665-5669 (2007).
2. Yu H, Jove R. The STATs of cancer - new molecular targets come of age. Nat. Rev. Cancer 4(2), 97-105 (2004).
3. Carro MS, Lim WK, Alvarez MJ et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 463(7279), 318-325 (2010).
4. Abdulghani J, Gu L, Dagvadorj A et al. Stat3 promotes metastatic progression of prostate cancer. Am. J. Pathol. 172(6), 1717-1728 (2008).
5. Corcoran RB, Contino G, Deshpande V et al. STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res. 71(14), 5020-5029 (2011).
6. Wright MW, Bruford EA. Naming 'junk': Human non-protein coding RNA (ncRNA) gene nomenclature. Hum. Genomics 5(2), 90-98 (2011).
7. Orom UA, Shiekhattar R. Long non-coding RNAs and enhancers. Curr. Opin Genet. Dev. 21(2), 194-198 (2011).
8. Huang K, Zhang JX, Han L et al. MicroRNA roles in beta-catenin pathway. Mol. Cancer 9, 252 (2010).
9. Thomson T, Lin H. The biogenesis and function of PIWI proteins and piRNAs: Progress and prospect. Annu. Rev. Cell Dev. Biol. 25, 355-376 (2009).
10. Dieci G, Preti M, Montanini B. Eukaryotic snoRNAs: A paradigm for gene expression flexibility. Genomics 94(2), 83-88 (2009).
11. Barbarotto E, Secchiero P, Dasgupta A, Fortina P, Calin GA, Hyslop T. MicroRNAs as new players in the genomic galaxy and disease puzzles. Clin. Transl Sci. 1(1), 50-56 (2008).
12. Farazi TA, Spitzer JI, Morozov P, Tuschl T. miRNAs in human cancer. J. Pathol. 223(2), 102-115 (2011).
13. Zhang CZ, Zhang JX, Zhang AL et al. miR 221 and miR 222 target PUMA to induce cell survival in glioblastoma. Mol. Cancer 9, 229 (2010).
14. Shi L, Cheng Z, Zhang J et al. hsa-miR 181a and hsa-miR 181b function as tumor suppressors in human glioma cells. Brain Res. 1236, 185-193 (2008).
15. Malecova B, Morris KV. Transcriptional gene silencing through epigenetic changes mediated by non-coding RNAs. Curr. Opin Mol. Ther. 12(2), 214-222 (2010).
16. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: Insights into functions. Nat. Rev. Genet. 10(3), 155-159 (2009).
17. Gibb EA, Brown CJ, Lam WL. The functional role of long non-coding RNA in human carcinomas. Mol. Cancer 10, 38 (2011).
18. Wapinski O, Chang HY. Long noncoding RNAs and human disease. Trends Cell Biol. 21(6), 354-361 (2011).
19. Hatziapostolou M, Polytarchou C, Aggelidou E et al. An HNF4a-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell 147(6), 1233-1247 (2011).
20. Fletcher S, Drewry JA, Shahani VM, Page BD, Gunning PT. Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein. Biochem. Cell Biol. 87(6), 825-833 (2009).
21. Page BD, Ball DP, Gunning PT. Signal transducer and activator of transcription 3 inhibitors: A patent review. Expert Opin Ther. Pat. 21(1), 65-83 (2011).
22. Chen CZ. MicroRNAs as oncogenes and tumor suppressors. N. Engl. J. Med. 353(17), 1768-1771 (2005).
23. Moretti F, Thermann R, Hentze MW. Mechanism of translational regulation by miR 2 from sites in the 5́ untranslated region or the open reading frame. RNA 16(12), 2493-2502 (2010).
24. Fang Z, Rajewsky N. The impact of miRNA target sites in coding sequences and in 3́UTRs. PLoS ONE 6(3), e18067 (2011).
25. Tsai NP, Lin YL, Wei LN. MicroRNA miR 346 targets the 5́-untranslated region of receptor-interacting protein 140 (RIP140) mRNA and up-regulates its protein expression. Biochem. J. 424(3), 411-418 (2009).
26. Shen WF, Hu YL, Uttarwar L, Passegue E, Largman C. MicroRNA-126 regulates HOXA9 by binding to the homeobox. Mol. Cell. Biol. 28(14), 4609-4619 (2008).
27. Carraro G, El-Hashash A, Guidolin D et al. miR 17 family of microRNAs controls FGF10-mediated embryonic lung epithelial branching morphogenesis through MAPK14 and STAT3 regulation of E-cadherin distribution. Dev. Biol. 333(2), 238-250 (2009).
28. Yan H, Wu J, Liu W et al. MicroRNA-20a overexpression inhibited proliferation and metastasis of pancreatic carcinoma cells. Hum. Gene Ther. 21(12), 1723-1734 (2010).
29. Cascio S, D'Andrea A, Ferla R et al. miR 20b modulates VEGF expression by targeting HIF-1 alpha and STAT3 in MCF-7 breast cancer cells. J. Cell. Physiol. 224(1), 242-249 (2010).
30. Pichiorri F, Suh SS, Ladetto M et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc. Natl Acad. Sci. USA 105(35), 12885-12890 (2008).
31. Brock M, Trenkmann M, Gay RE et al. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. Circ. Res. 104(10), 1184-1191 (2009).
32. Dai B, Meng J, Peyton M et al. STAT3 mediates resistance to MEK inhibitor through microRNA miR 17. Cancer Res. 71(10), 3658-3668 (2011).
33. Kong W, He L, Coppola M et al. MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J. Biol. Chem. 285(23), 17869-17879 (2010).
34. Donnem T, Eklo K, Berg T et al. Prognostic impact of miR 155 in non-small cell lung cancer evaluated by in situ hybridization. J. Transl Med. 9, 6 (2011).
35. Greither T, Grochola LF, Udelnow A, Lautenschlager C, Wurl P, Taubert H. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int. J. Cancer 126(1), 73-80 (2010).
36. Jiang S, Zhang HW, Lu MH et al. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 70(8), 3119-3127 (2010).
37. Johnson SM, Grosshans H, Shingara J et al. RAS is regulated by the let-7 microRNA family. Cell 120(5), 635-647 (2005).
38. Sampson VB, Rong NH, Han J et al. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res. 67(20), 9762-9770 (2007).
39. Wang Y, Lu Y, Toh ST et al. Lethal-7 is down-regulated by the hepatitis B virus x protein and targets signal transducer and activator of transcription 3. J. Hepatol. 53(1), 57-66 (2010).
40. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 microRNA, and IL6 links inflammation to cell transformation. Cell 139(4), 693-706 (2009).
41. Loffler D, Brocke-Heidrich K, Pfeifer G et al. Interleukin-6 dependent survival of multiple myeloma cells involves the STAT3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 110(4), 1330-1333 (2007).
42. Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K. STAT3 activation of miR 21 and miR 181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol. Cell 39(4), 493-506 (2010).
43. Ohno M, Natsume A, Kondo Y et al. The modulation of microRNAs by type I IFN through the activation of signal transducers and activators of transcription 3 in human glioma. Mol. Cancer Res. 7(12), 2022-2030 (2009).
44. Haider KH, Idris NM, Kim HW, Ahmed RP, Shujia J, Ashraf M. MicroRNA-21 is a key determinant in IL-11/Stat3 anti-Apoptotic signalling pathway in preconditioning of skeletal myoblasts. Cardiovasc. Res. 88(1), 168-178 (2010).
45. Ren Y, Zhou X, Mei M et al. MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol. BMC Cancer 10, 27 (2010).
46. Surdziel E, Cabanski M, Dallmann I et al. Enforced expression of miR 125b affects myelopoiesis by targeting multiple signaling pathways. Blood 117(16), 4338-4348 (2011).
47. Moffatt CE, Lamont RJ. Porphyromonas gingivalis induction of microRNA-203 expression controls suppressor of cytokine signaling 3 in gingival epithelial cells. Infect. Immun. 79(7), 2632-2637 (2011).
48. Courboulin A, Paulin R, Giguere NJ et al. Role for miR 204 in human pulmonary arterial hypertension. J. Exp. Med. 208(3), 535-548 (2011).
49. Wang B, Hsu S, Frankel W, et al. Stat3- mediated activation of miR-23a suppresses gluconeogenesis in hepatocellular carcinoma by downregulating G6PC and PGC 1a. Hepatology doi:10.1002/hep.25632. (2012) (Epub ahead of print).
50. Jia H, Osak M, Bogu GK, Stanton LW, Johnson R, Lipovich L. Genome-wide computational identification and manual annotation of human long noncoding RNA genes. RNA 16(8), 1478-1487 (2010).
51. Song H, Wang R, Wang S, Lin J. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc. Natl Acad. Sci. USA 102(13), 4700-4705 (2005).
52. Lin L, Hutzen B, Zuo M et al. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res. 70(6), 2445-2454 (2010).
53. Lin L, Deangelis S, Foust E et al. A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells. Mol. Cancer 9, 217 (2010).
54. Turkson J, Zhang S, Mora LB, Burns A, Sebti S, Jove R. A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J. Biol. Chem. 280(38), 32979-32988 (2005).
55. Leong PL, Andrews GA, Johnson De et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc. Natl Acad. Sci. USA 100(7), 4138-4143 (2003).
56. Zhang X, Zhang J, Wang L, Wei H, Tian Z. Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice. BMC Cancer 7, 149 (2007).
57. Zhang X, Liu P, Zhang B, Wang A, Yang M. Role of STAT3 decoy oligodeoxynucleotides on cell invasion and chemosensitivity in human epithelial ovarian cancer cells. Cancer Genet. Cytogenet. 197(1), 46-53 (2010).
58. Yang M, Mattes J. Discovery, biology and therapeutic potential of RNA interference, microRNA and antagomirs. Pharmacol. Ther. 117(1), 94-104 (2008).
59. Obad S, dos Santos CO, Petri A et al. Silencing of microRNA families by seed-targeting tiny LNAs. Nat. Genet. 43(4), 371-378 (2011).
60. Zhang S, Chen L, Jung EJ, Calin GA. Targeting microRNAs with small molecules: From dream to reality. Clin. Pharmacol. Ther. 87(6), 754-758 (2010).
61. Faghihi MA, Modarresi F, Khalil AM et al. Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase. Nat. Med. 14(7), 723-730 (2008).
62. Gupta RA, Shah N, Wang KC et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464(7291), 1071-1076 (2010).
63. Parisien M, Major F. The MC-Fold and MC-Sym pipeline infers RNA structure from sequence data. Nature 452(7183), 51-55 (2008).